STOCK TITAN

Haemonetics 4th Quarter Fiscal Year 2022 Earnings Release Available on Investor Relations Website

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Financial release accessible online

BOSTON, May 10, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal 2022, which ended April 2, 2022, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. EDT on May 10, 2022. The conference call and webcast can be accessed with the following information:

  • U.S. / Canada toll free (877) 848-8880; International (716) 335-9512
  • Conference ID required for access: 5347317
  • A live webcast of the call can be accessed on Haemonetics' Investor Relations website or via the following link: https://edge.media-server.com/mmc/p/gooqch6s

In addition, the Company has posted to its Investor Relations website the earnings release and analytical tables and supplemental information that will be referenced on its conference call and webcast, direct links to which are available below.  

Direct link to 4Q FY22 Earnings Release:
https://haemonetics.gcs-web.com/static-files/864cad71-8258-4574-a33e-beaddcb84f33

Direct link to 4Q FY22 Analytical Tables and Supplemental Information:
https://haemonetics.gcs-web.com/static-files/52e9f8bf-c0fc-490a-af79-5fe4fef86e06

A replay of the conference call and webcast will be available for one year beginning on May 10, 2022, at 11:00 a.m. EDT using the conference call webcast link provided in this press release.

About Haemonetics
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:


Olga Guyette, Sr. Director-Investor Relations & Treasury

David Trenk, Manager-Investor Relations

(781) 356-9763

(203) 733-4987

olgaguyette@haemoneticscom

davidtrenk@haemoneticscom



Media Contact:


Josh Gitelson, Director-Global Communications


(781) 356-9776


josh.gitelson@haemoneticscom


 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-4th-quarter-fiscal-year-2022-earnings-release-available-on-investor-relations-website-301543450.html

SOURCE Haemonetics Corporation

Haemonetics Corporation

NYSE:HAE

HAE Rankings

HAE Latest News

HAE Stock Data

4.49B
50.37M
0.76%
101.04%
4.01%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
BOSTON

About HAE

haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right